This bill aims to improve diabetes management in Florida by enhancing healthcare access and medication availability. It requires the Department of Health to establish a website that assists individuals in finding referrals to federally qualified health centers, which must make a good faith effort to schedule appointments within 30 days. Additionally, pharmacists are authorized to prescribe and dispense a 30-day supply of insulin and other diabetes-related medications, ensuring that patients are charged no more than their insurance copayment or the usual cost if uninsured. The bill also mandates health insurance policies and health maintenance contracts to cover laboratory and diagnostic testing for diabetes, while capping cost-sharing for diabetes medications and devices at $35 for insulin or glucagon drugs and $100 for diabetes devices.

Moreover, the bill introduces new provisions regarding health maintenance contracts and modifies the prescription drug monitoring program. It establishes a maximum out-of-pocket expense for diabetes-related medications and devices, effective for contracts issued or renewed after January 1, 2026. The bill also redesignates existing subsections of the prescription drug monitoring program, adding new requirements for program management and mandating the reporting of all insulin drugs, glucagon drugs, and diabetes devices. The program manager is granted the authority to share relevant information with prescribers, dispensers, and law enforcement as needed. The act is set to take effect on July 1, 2025.